First generation TKI plus something in EGFR mutant NSCLC

Dr. Akhil Kapoor

Associate Professor, Medical Oncology

Tata Memorial Hospital (HBCH & MPMMCC), Varanasi





Background

• We all love to give Osimertinib in EGFR mutant NSCLC.

Reasons:

- Well tolerated
- Oral treatment
- Very good outcomes (usually)
- Issue: Affordability
- Generic not going to come, Patent till 2035 !!!!!!

Alternative Strategies


- Gefitinib plus Chemotherapy
- TKI plus Metformin
- TKI plus Bevacizumab

Gefitinib plus Chemotherapy

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer Vanita Noronha, MBBS, MD, DM¹; Vijay Maruti Patil, MBBS, MD, DM¹; Amit Joshi, MBBS, MD, DM¹; Nandini Menon, MBBS, MD, DN Anuradha Chougule, PhD¹; Abhishek Mahajan, MBBS, MD, MRes¹; Amit Janu, MBBS, DMRD, DNB¹; Nilendu Purandare, MBBS, DN Baiju Kumar, MBBS, MD¹: Sucheta More, BAMS, MSc¹: Supriva Goud, BAMS¹: Nandkumar Kadam, BSc²: Nilesh Daware, HSc²:

Vanita Noronha, MBBS, MD, DM¹; Vijay Maruti Patil, MBBS, MD, DM¹; Amit Joshi, MBBS, MD, DM¹; Nandini Menon, MBBS, MD, DNB¹; Anuradha Chougule, PhD¹; Abhishek Mahajan, MBBS, MD, MRes¹; Amit Janu, MBBS, DMRD, DNB¹; Nilendu Purandare, MBBS, DNB¹; Rajiv Kumar, MBBS, MD¹; Sucheta More, BAMS, MSc¹; Supriya Goud, BAMS¹; Nandkumar Kadam, BSc²; Nilesh Daware, HSc²; Atanu Bhattacharjee, MSc, PhD¹; Srushti Shah, BHMS, PDCR¹; Akanksha Yadav, MSc¹; Vaishakhi Trivedi, MSc¹; Vichitra Behel, MTech¹; Amit Dutt, PhD³; Shripad Dinanath Banavali, MBBS, MD¹; and Kumar Prabhash, MBBS, MD, DM¹

Gefitinib ± Carboplatin/Pemetrexed As First-Line Therapy for EGFR-Mutant NSCLC



• Primary endpoint: PFS

Stratified by ECOG PS and EGFR mutation subtype

• Secondary endpoints: OS, toxicity, QoL

Noronha et al. ASCO 2019


Included rare mutations as well: Real world Scenario

Characteristic	Gef+C (n = 174)	Gef (n = 176)	
Presence of brain metastases ^e	30 (17)	34 (19)	
Presence of pulmonary embolism ^f	7 (4)	2 (1)	
EGFR mutation type			
Exon 19 in-frame deletion	107 (62)	109 (62)	
Exon 21 (L858R/L861Q)	60 (35)	60 (34)	
Exon 18 (G719X)	1 (1)	2 (1)	
Exon 20 (T790M) with additional sensitizing mutation ^g	4 (2)	2 (1)	
Dual sensitizing mutation ^h	2 (1)	3 (2)	

Gefitinib vs Gefitinib + chemotherapy TMH


Panel A

Arm	Number of patients	Number of events	Median PFS (95%CI)
Gefitinib	176	138	8 months (7.0 to 9.0)
Gefitinib + pemetrexed/carboplatin	174	99	16 months (13.5 to 18.5)



Panel B

Arm	Number of patients	Number of events	Median OS (95%CI)
Gefitinib	176	80	17 months (13.5 to 20.5)
Gefitinib + pemetrexed/carboplatin	174	42	NC (NC to NC)





 Gefitnib+Pem/Carbo Arm Gefitinib

ORR

75% versus 62%

P=0.01





• PFS time: 8 m Vs. 16 m

• OS: 18-month OS rates were 48.7% and 74.3%

• PFS2 time was 14 months and 23 months.

Characteristic	Gefitinib Plus Pemetrexed and Carboplatin Arm	Gefitinib Arm		Hazard Ratio (95% CI)
Age at screening, yea			··-·-·-·-·-·-·-·	
≤ 6 0	73/131	99/119		0.45 (0.33 to 0.61)
> 60	26/43	39/57	_ 	0.65 (0.39 to 1.08)
Sex				
Male	55/88	73/93		0.59 (0.42 to 0.84)
Female	44/86	65/83		0.43 (0.29 to 0.64)
Exon mutation at rand	dom assignment			
Exon 19	58/109	86/110		0.49 (0.35 to 0.69)
Others	41/65	52/66		0.53 (0.35 to 0.8)
Brain metastases				
Present	19/30	27/34		0.53 (0.29 to 0.98)
Absent	80/144	111/142		0.51 (0.38 to 0.68)
ECOG performance st	atus			
0 or 1	75/138	106/137		0.48 (0.36 to 0.65)
2	24/36	32/39	_ 	0.57 (0.33 to 0.98)
Overall	99/174	138/176		0.51 (0.39 to 0.66)
			0 1	2
		pem	gefitinib plus F etrexed and oplatin arm	avors gefitinib arm

No. of Events/No. of Patients



- Benefit came at the price of a doubling of serious clinically relevant toxicities, from 25% to 51%.
- Chemotherapy-induced myelosupression and nephrotoxicity.
- FN rates 11%, 1 death
- Fatigue not statistically different, but in clinical practice seems to be higher constantly

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJOO9 Study

Yukio Hosomi, MD, PhD¹; Satoshi Morita, PhD²; Shunichi Sugawara, MD, PhD³; Terufumi Kato, MD⁴; Tatsuro Fukuhara, MD, PhD⁵; Akihiko Gemma, MD, PhD⁶; Kazuhisa Takahashi, MD, PhD⁷; Yuka Fujita, MD, PhD⁸; Toshiyuki Harada, MD, PhD⁹; Koichi Minato, MD¹⁰; Kei Takamura, MD¹¹; Koichi Hagiwara, MD, PhD¹²; Kunihiko Kobayashi, MD, PhD¹³; Toshihiro Nukiwa, MD, PhD¹⁴; and Akira Inoue, MD, PhD¹⁵ for the North-East Japan Study Group

PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung cancer (NSCLC) with EGFR mutations; however, little is known about the efficacy and safety of this combination compared with that of standard therapy with EGFR- tyrosine kinase inhibitors alone.

METHODS We randomly assigned 345 patients with newly diagnosed metastatic NSCLC with EGFR mutations to gefitinib combined with carboplatin plus pemetrexed or gefitinib alone. Progression-free survival (PFS), PFS2, and overall survival (OS) were sequentially analyzed as primary end points according to a hierarchical sequential

Inclusion Criteria







Normal marrow, renal, liver function

Exclusion Criteria

Interstitial pneumonia or pulmonary fibrosis

ð

Ųŗ

EGFR T790M Mutation

Å

Geftinib or pemtrexed as pre- or postoperative adjuvant therapy

Symptomatic brain metastasis (enrollment accepted if symptoms disappear after RT)

RT for the primary lesion


Gp

Serious complications (poorly controlled psychiatric, pulmonary, hepatic or renal disease, DM)




Marked malabsorption syndrome, diseases affecting GI function (post gastrectomy, gastric and duodenal ulcers, active IBD)


Results-ORR




Results-PFS/PFS2/OS



Results-





Clinical status at PD1 and PD2

	Gefitinib (n=172)	Gefitinib+CBDCA+PEM (n=169)
PD1	n=153	n=135
ECOG PS, n (%) 0-1 / 2 / 3-4	134 (87.6) / 8 (5.2) / 3 (2.0)	116 (85.9) / 12 (8.9) / 4 (2.9)
Number of metastatic organs median (range)	1 (0-5)	1 (0-7)
Brain metastasis, n (%)	38 (24.8)	48 (35.6)
PD2	n=128	Tumor burden
ECOG PS, n (%) 0-1/2/3-4	88 (68.8) / 19 (14.8) / 11 (8.6)	PD2 PD1 Platinum
Number of metastatic organs median (range)	2 (0-6)	Gentinib Combination
Brain metastasis, n (%)	38 (29.7)	0 Time




#ASCO18 Stides are the property of the author, permission required for reser.

PRESENTED BY: Atsushi Nakamura

Phase III NEJ026: Erlotinib ± Bevacizumab in *EGFR*-Mutated Advanced NSCLC


- Chemotherapy-naive patients IIIB/IV or recurrent nonsquamous NSCLC
- EGFR mutation +ve (exon 19 deletion or L858R, no T790M)
- ECOG PS ≤ 2
- asymptomatic CNS mets allowed
- (N = 228)



Stratified by sex, stage, EGFR mutation, and smoking history

- Primary endpoint: PFS by independent review
- Secondary endpoints: OS, tumor response, DoR, QoL, safety

Saito. Lancet Oncol. 2019;20:625.



Ramucirumab plus erlotinib in patients with untreated, *EGFR*-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Prof Kazuhiko Nakagawa, MD 🛛 😤 🖻 🛛 Edward B Garon, MD 🔹 Takashi Seto, MD 🔹 Makoto Nishio, MD 🔹

Santiago Ponce Aix, MD • Prof Luis Paz-Ares, MD • et al. Show all authors • Show footnotes

Published: October 04, 2019 • DOI: https://doi.org/10.1016/S1470-2045(19)30634-5 •

Check for updates

PDF [1 MB]

Summary

Background

Dual blockade of the EGFR and VEGF pathways in *EGFR*-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase





Figure 2: Kaplan-Meier estimates of investigator-assessed progression-free survival

What Information will help improve our treatment decisions? Are all EGFR mutations equal?





Uncommon EGFR mutations

Exon 20 Insertion

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis




Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS

ТКІ	HR _{19/21} of <u>TKI</u> ª for PFS (95% CI	I) P-value
Gefitinib		
Erlotinib	Significantly reduced risk of disease progression for Exon 19 del vs L858R	
Afatinib	progression for Exon 15 dervs	SLOJON
Overall	0.59 (0.38-0.92)	0.019

^aHR_{19/21} of TKI represent HR₁₉ exon deletion/exon 21 L858R mutation in TKI therapy cohort



Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis



Direct meta-analysis

7 studies


549 patients

EGFR TKI (monotherapy - 1st or 2nd generation) vs CT

L858R: Higher Incidence of Concomitant Mutation and Poor outcome




Retrospective cohort study1 from Sun <u>Yat-sen</u> University Cancer Center, China, 2012-2014, 58 cases with EGFRm advanced NSCLC. Cell-free DNA obtained before treatment was subjected to NGS of 49 cancer-related genes




A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Kristen A. Marrone, Xian Zhou, Patrick M. Forde, Michael Purtell, Julie R. Brahmer, Christine L. Hann, Ronan J. Kelly, Barbara Coleman, Edward Gabrielson, Gary L. Rosner, David S. Ettinger 🐱

First published: 27 February 2018 | https://doi.org/10.1634/theoncologist.2017-0465 | Citations: 4



- The 1-year PFS on Arm A was 47% (95% CI: 25%–88%), with the 95% lower confidence bound greater than 15%, the hypothesized 1-year PFS without metformin.
- The median PFS was 9.6 months (95% CI: 7.3– not applicable [NA]) for Arm A and 6.7 months (95% CI: 4.4–NA) for Arm B




- The 1-year OS on Arm A was 68% (95% CI: 48%–92%), compared with the historical probability of 51%.
- Median OS of patients treated on Arm A was 15.9 months (95% CI: 8.4–NA) and 13.9 months (95% CI: 12.7–NA) on Arm B; the difference was not statistically significant (p = .186).


Research


JAMA Oncology | Original Investigation

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma A Phase 2 Randomized Clinical Trial


Oscar Arrieta, MD, MSc; Feliciano Barrón, MD; Miguel-Ángel Salinas Padilla, MD; Alejandro Avilés-Salas, MD; Laura Alejandra Ramírez-Tirado, MD, MSc; Manuel Jesús Arguelles Jiménez, MD; Edgar Vergara, MD, PhD; Zyanya Lucia Zatarain-Barrón, MD, MSc; Norma Hernández-Pedro, PhD; Andrés F. Cardona, MD, PhD; Graciela Cruz-Rico, PhD; Pedro Barrios-Bernal, BBs; Masao Yamamoto Ramos, MD; Rafael Rosell, MD, PhD








B Progression-free survival (radiooncologist 2)



D Overall survival comparison



Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial



Clinical


Cancer

Research

Li Li¹, Liyan Jiang², Yubo Wang¹, Yizhuo Zhao², Xiao-Ju Zhang³, Guoming Wu⁴, Xiangdong Zhou⁵, Jianguo Sun⁶, Jun Bai⁷, Biyong Ren⁸, Kun Tian⁹, Zhi Xu⁴, Hua-liang Xiao¹⁰, Qi Zhou¹¹, Rui Han¹, Hengyi Chen¹, Haidong Wang¹², Zhenzhou Yang¹³, Chan Gao¹⁴, Shangli Cai¹⁴, and Yong He¹

Results

- n=224
- Median PFS (10.3 months vs. 11.4 months)
- Median OS (22.0 months vs. 27.5 months) were numerically lower in the metformin group
- ORRs were similar between the two arms (66% vs. 66.7%).



CHOOSING WISELY REMAINS THE KEY

THANKS and GREETING FROM TMH VARANASI

